Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will
View HTML
Toggle Summary Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will
View HTML
Toggle Summary Sage Therapeutics to Host Conference Call
Announcing Positive Phase 3 Results for Zuranolone, an Investigational Two-Week, Once Daily Therapeutic Being Evaluated for Major Depressive Disorder Webcast scheduled for 8:00a.m. ET on Tuesday, June 15 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2021-- Sage Therapeutics (Nasdaq: SAGE), a
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in HAMD-17 results at Days 3, 8, and 12 Patients with a
View HTML
Toggle Summary Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
Creating a movement from the inside out – to break the stigma of mental health conditions and empower employees to be champions of brain health Learn more at www.MentalHealthActionDay.org CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 20, 2021-- Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company
View HTML
Toggle Summary Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth
Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m.
View HTML
Toggle Summary Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Company on-track to initiate placebo-controlled Phase 2 trial with SAGE-718 in Huntington’s disease in late 2021, as the target for the first indication for SAGE-718, following encouraging signals in Phase 1 data PARADIGM Study with SAGE-718 showed improved performance from baseline on multiple
View HTML
Toggle Summary Sage Therapeutics to Present at Upcoming May Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 28, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML